Molecular Glue - A New Way to Stick it to Cancer - Andrew Mitchell

This research targets chronic lymphocytic leukemia relapse by focusing on Bruton’s Tyrosine Kinase (BTK), a key cancer-driving protein that often mutates and becomes drug-resistant. Using “molecular glues,” the project aims to degrade BTK—even when mutated—offering a new therapeutic strategy that could overcome resistance and improve outcomes for (chronic lymphocytic leukemia) CLL and other BTK-dependent cancers.